JP2024527380A - 腎機能障害を有する個体へのオリゴヌクレオチドの使用 - Google Patents
腎機能障害を有する個体へのオリゴヌクレオチドの使用 Download PDFInfo
- Publication number
- JP2024527380A JP2024527380A JP2024501166A JP2024501166A JP2024527380A JP 2024527380 A JP2024527380 A JP 2024527380A JP 2024501166 A JP2024501166 A JP 2024501166A JP 2024501166 A JP2024501166 A JP 2024501166A JP 2024527380 A JP2024527380 A JP 2024527380A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- rnai
- administered
- rnai agent
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163220400P | 2021-07-09 | 2021-07-09 | |
| US63/220,400 | 2021-07-09 | ||
| PCT/IB2022/056278 WO2023281434A1 (en) | 2021-07-09 | 2022-07-07 | Use of oligonucleotides for individuals with renal impairment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024527380A true JP2024527380A (ja) | 2024-07-24 |
| JP2024527380A5 JP2024527380A5 (cg-RX-API-DMAC7.html) | 2025-07-08 |
Family
ID=82703082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024501166A Pending JP2024527380A (ja) | 2021-07-09 | 2022-07-07 | 腎機能障害を有する個体へのオリゴヌクレオチドの使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240336921A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4367241A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024527380A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117616121A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3224600A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202323525A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023281434A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025242321A1 (en) | 2024-05-24 | 2025-11-27 | Glaxosmithkline Intellectual Property (No.3) Limited | Novel use |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| WO2000053722A2 (en) | 1999-03-10 | 2000-09-14 | Phogen Limited | Delivery of nucleic acids and proteins to cells |
| EA008940B1 (ru) | 2002-09-13 | 2007-10-26 | Репликор, Инк. | Антивирусные олигонуклеотиды, не связанные с комплементарностью последовательностей |
| CN101500548A (zh) | 2006-08-18 | 2009-08-05 | 弗·哈夫曼-拉罗切有限公司 | 用于体内递送多核苷酸的多缀合物 |
| PH12012501596A1 (en) | 2010-02-24 | 2017-02-03 | Arrowhead Res Corporation | Compositions for targeted delivery of sirna |
| JP5775581B2 (ja) | 2010-08-20 | 2015-09-09 | レプリコール インコーポレーティッド | オリゴヌクレオチドキレート錯体 |
| US8501930B2 (en) | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
| KR20170029577A (ko) | 2014-07-10 | 2017-03-15 | 레플리코르 인코포레이티드 | B형 간염 및 d형 간염 바이러스 감염의 치료 방법 |
| JOP20190015A1 (ar) * | 2016-08-04 | 2019-02-04 | Arrowhead Pharmaceuticals Inc | عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب |
| EA202091513A1 (ru) | 2017-12-19 | 2020-09-09 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Вакцины против вируса гепатита b (hbv) и их применение |
| US20200147124A1 (en) | 2018-11-08 | 2020-05-14 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| TWI872048B (zh) * | 2019-02-07 | 2025-02-11 | 美商艾羅海德製藥公司 | 用於B型肝炎病毒感染之RNAi劑 |
| TW202103698A (zh) * | 2019-04-18 | 2021-02-01 | 美商健生醫藥公司 | 用於治療b型肝炎病毒感染之組合療法 |
| US20200332297A1 (en) * | 2019-04-18 | 2020-10-22 | Janssen Pharmaceuticals, Inc. | Combination therapy for treating hepatitis b virus infection |
-
2022
- 2022-07-07 CN CN202280048358.4A patent/CN117616121A/zh active Pending
- 2022-07-07 CA CA3224600A patent/CA3224600A1/en active Pending
- 2022-07-07 JP JP2024501166A patent/JP2024527380A/ja active Pending
- 2022-07-07 EP EP22747759.3A patent/EP4367241A1/en active Pending
- 2022-07-07 WO PCT/IB2022/056278 patent/WO2023281434A1/en not_active Ceased
- 2022-07-07 US US18/577,450 patent/US20240336921A1/en active Pending
- 2022-07-08 TW TW111125691A patent/TW202323525A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN117616121A (zh) | 2024-02-27 |
| US20240336921A1 (en) | 2024-10-10 |
| WO2023281434A1 (en) | 2023-01-12 |
| TW202323525A (zh) | 2023-06-16 |
| EP4367241A1 (en) | 2024-05-15 |
| CA3224600A1 (en) | 2023-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7763907B2 (ja) | B型肝炎ウイルス感染のためのRNAi薬 | |
| US20230357773A1 (en) | Oligonucleotide treatment of hepatitis b patients | |
| US12582668B2 (en) | Methods for the treatment of alpha-1 antitrypsin deficiency (AATD) | |
| WO2021263271A1 (en) | Compositions and methods for treatment of hepatitis d virus infection | |
| CN111065413A (zh) | TACI-Fc融合蛋白用于制备治疗视神经脊髓炎谱系疾病和多发性硬化之药物中的应用 | |
| US20200330499A1 (en) | Combination therapy for treating hepatitis b virus infection | |
| WO2016164619A2 (en) | Compositions and methods for the treatment of hbv infection | |
| US20220249488A1 (en) | Toll-like receptor agonists for use in the treatment of hepatitis b | |
| US20210285000A1 (en) | Combination therapy for treating hepatitis b virus infection | |
| CN121152807A (zh) | 使用抗cd40l抗体治疗多发性硬化症 | |
| JP2024514126A (ja) | アジア人患者における多発性硬化症を治療するためのオファツムマブ | |
| WO2022152869A1 (en) | Use of oligonucleotides for individuals with hepatic impairment | |
| EP4367241A1 (en) | Use of oligonucleotides for individuals with renal impairment | |
| TW202220675A (zh) | 降低z-aat蛋白水準之方法 | |
| EP4695395A1 (en) | Methods of treating chronic hepatitis b | |
| KR20220121793A (ko) | 이식편대숙주 질환의 예방 또는 치료에 있어서의 화합물의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250630 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250630 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260807 |